At its meeting on 22 August 2022 the Transparency Council adopted Position No. 77/2022 on the evaluation of drug Tremfya (guselkumab) under the drug programme: ,,Treatment of moderate and severe plaque psoriasis (ICD-10: L40.0)”.
Publication in Public Information Bulletin (BIP)